Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary

Lilla Pogácsás, András Borsi, Péter Takács, Éva Remenyik, Lajos Kemény, Sarolta Kárpáti, Péter Holló, Norbert Wikonkál, Rolland Gyulai, Zsuzsanna Károlyi, Pál Rakonczai, Tamás Balázs, Andrea Szegedi

Research output: Article

10 Citations (Scopus)

Abstract

Persistence is an important component of therapeutic success, which depends on a variety of factors. Persistence measured under optimal conditions during clinical trials does not necessarily coincide with persistence observed in the real-world settings. The aim of the present study was to compare persistence rate of TNF-alpha inhibitors and interleukin 12/23 inhibitor in all psoriasis patients in Hungary, as well as to analyze the predictors of persistence. Data collected from 1263 patients over a period of 46 months were subjected to a retrospective analysis. Drug survival rate has been calculated according to Kaplan–Meier analysis and Cox regression was used to study the predictors. The overall persistence rate for the four biologicals exceeded 60% after 3 years. The persistence rate of ustekinumab at 3 years was 67.83%, which was superior compared to that of the TNF-alpha inhibitors, where the mean persistence rate was shown to be 50.76% (p <.05). Male patients showed significantly higher persistence than females (HR =.76, p <.05 CI: 0.63, 0.92). Age, therapy-naïve status and use of concomitant MTX did not have significant effect on drug survival. Persistence rate of ustekinumab was significantly higher than that of TNF-alpha inhibitors, and among predictors, only male gender influenced persistence significantly.

Original languageEnglish
Pages (from-to)635-641
Number of pages7
JournalJournal of Dermatological Treatment
Volume28
Issue number7
DOIs
Publication statusPublished - okt. 3 2017

Fingerprint

Biological Therapy
Hungary
Survival Analysis
Tumor Necrosis Factor-alpha
Pharmaceutical Preparations
Population
Interleukin-23
Interleukin-12
Psoriasis
Survival Rate
Regression Analysis
Clinical Trials
Survival
Therapeutics
Ustekinumab

ASJC Scopus subject areas

  • Dermatology

Cite this

Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary. / Pogácsás, Lilla; Borsi, András; Takács, Péter; Remenyik, Éva; Kemény, Lajos; Kárpáti, Sarolta; Holló, Péter; Wikonkál, Norbert; Gyulai, Rolland; Károlyi, Zsuzsanna; Rakonczai, Pál; Balázs, Tamás; Szegedi, Andrea.

In: Journal of Dermatological Treatment, Vol. 28, No. 7, 03.10.2017, p. 635-641.

Research output: Article

@article{2bfaaaf0a3ad473e961e2020dc215418,
title = "Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary",
abstract = "Persistence is an important component of therapeutic success, which depends on a variety of factors. Persistence measured under optimal conditions during clinical trials does not necessarily coincide with persistence observed in the real-world settings. The aim of the present study was to compare persistence rate of TNF-alpha inhibitors and interleukin 12/23 inhibitor in all psoriasis patients in Hungary, as well as to analyze the predictors of persistence. Data collected from 1263 patients over a period of 46 months were subjected to a retrospective analysis. Drug survival rate has been calculated according to Kaplan–Meier analysis and Cox regression was used to study the predictors. The overall persistence rate for the four biologicals exceeded 60{\%} after 3 years. The persistence rate of ustekinumab at 3 years was 67.83{\%}, which was superior compared to that of the TNF-alpha inhibitors, where the mean persistence rate was shown to be 50.76{\%} (p <.05). Male patients showed significantly higher persistence than females (HR =.76, p <.05 CI: 0.63, 0.92). Age, therapy-na{\"i}ve status and use of concomitant MTX did not have significant effect on drug survival. Persistence rate of ustekinumab was significantly higher than that of TNF-alpha inhibitors, and among predictors, only male gender influenced persistence significantly.",
keywords = "Biological therapy, comparison, hazard ratios, persistence, predictors, psoriasis",
author = "Lilla Pog{\'a}cs{\'a}s and Andr{\'a}s Borsi and P{\'e}ter Tak{\'a}cs and {\'E}va Remenyik and Lajos Kem{\'e}ny and Sarolta K{\'a}rp{\'a}ti and P{\'e}ter Holl{\'o} and Norbert Wikonk{\'a}l and Rolland Gyulai and Zsuzsanna K{\'a}rolyi and P{\'a}l Rakonczai and Tam{\'a}s Bal{\'a}zs and Andrea Szegedi",
year = "2017",
month = "10",
day = "3",
doi = "10.1080/09546634.2017.1329504",
language = "English",
volume = "28",
pages = "635--641",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary

AU - Pogácsás, Lilla

AU - Borsi, András

AU - Takács, Péter

AU - Remenyik, Éva

AU - Kemény, Lajos

AU - Kárpáti, Sarolta

AU - Holló, Péter

AU - Wikonkál, Norbert

AU - Gyulai, Rolland

AU - Károlyi, Zsuzsanna

AU - Rakonczai, Pál

AU - Balázs, Tamás

AU - Szegedi, Andrea

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Persistence is an important component of therapeutic success, which depends on a variety of factors. Persistence measured under optimal conditions during clinical trials does not necessarily coincide with persistence observed in the real-world settings. The aim of the present study was to compare persistence rate of TNF-alpha inhibitors and interleukin 12/23 inhibitor in all psoriasis patients in Hungary, as well as to analyze the predictors of persistence. Data collected from 1263 patients over a period of 46 months were subjected to a retrospective analysis. Drug survival rate has been calculated according to Kaplan–Meier analysis and Cox regression was used to study the predictors. The overall persistence rate for the four biologicals exceeded 60% after 3 years. The persistence rate of ustekinumab at 3 years was 67.83%, which was superior compared to that of the TNF-alpha inhibitors, where the mean persistence rate was shown to be 50.76% (p <.05). Male patients showed significantly higher persistence than females (HR =.76, p <.05 CI: 0.63, 0.92). Age, therapy-naïve status and use of concomitant MTX did not have significant effect on drug survival. Persistence rate of ustekinumab was significantly higher than that of TNF-alpha inhibitors, and among predictors, only male gender influenced persistence significantly.

AB - Persistence is an important component of therapeutic success, which depends on a variety of factors. Persistence measured under optimal conditions during clinical trials does not necessarily coincide with persistence observed in the real-world settings. The aim of the present study was to compare persistence rate of TNF-alpha inhibitors and interleukin 12/23 inhibitor in all psoriasis patients in Hungary, as well as to analyze the predictors of persistence. Data collected from 1263 patients over a period of 46 months were subjected to a retrospective analysis. Drug survival rate has been calculated according to Kaplan–Meier analysis and Cox regression was used to study the predictors. The overall persistence rate for the four biologicals exceeded 60% after 3 years. The persistence rate of ustekinumab at 3 years was 67.83%, which was superior compared to that of the TNF-alpha inhibitors, where the mean persistence rate was shown to be 50.76% (p <.05). Male patients showed significantly higher persistence than females (HR =.76, p <.05 CI: 0.63, 0.92). Age, therapy-naïve status and use of concomitant MTX did not have significant effect on drug survival. Persistence rate of ustekinumab was significantly higher than that of TNF-alpha inhibitors, and among predictors, only male gender influenced persistence significantly.

KW - Biological therapy

KW - comparison

KW - hazard ratios

KW - persistence

KW - predictors

KW - psoriasis

UR - http://www.scopus.com/inward/record.url?scp=85027159827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027159827&partnerID=8YFLogxK

U2 - 10.1080/09546634.2017.1329504

DO - 10.1080/09546634.2017.1329504

M3 - Article

VL - 28

SP - 635

EP - 641

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 7

ER -